Document is current
Any future updates will be listed below
-
Authors
Murgaš, Matej https://orcid.org/0000-0001-7643-2182
Milz, Christian https://orcid.org/0000-0002-1347-0744
Stöhrmann, Peter https://orcid.org/0000-0002-7324-0414
Unterholzner, Jakob https://orcid.org/0000-0001-9274-6990
Nics, Lukas
Kranz, Georg S. https://orcid.org/0000-0002-3892-1804
Hahn, Andreas https://orcid.org/0000-0001-9727-7580
Hacker, Marcus https://orcid.org/0000-0002-4222-4083
Kasper, Siegfried https://orcid.org/0000-0001-8278-191X
Lanzenberger, Rupert https://orcid.org/0000-0003-4641-9539
Godbersen, Godber M. https://orcid.org/0000-0002-9739-0724
-
Funding
Funding for this research was provided by:
Österreichischen Akademie der Wissenschaften (DOC27221)
Austrian Science Fund (DI_2023‐110, https://doi.org/10.55776/KLI551, https://doi.org/10.55776/KLI1006, https://doi.org/10.55776/DOC33)
Else Kröner-Fresenius-Stiftung (2014_A192)
Vienna Science and Technology Fund (https://doi.org/10.47379/CS18039)
- License Information
-
More Information
Article History
Received: 12 February 2025
Revised: 7 May 2025
Accepted: 21 May 2025
First Online: 3 June 2025
Competing interests
: In the past three years S. Kasper has received grant/research support from Lundbeck; he has served as a consultant or on advisory boards for Angelini, Biogen, Esai, Janssen, IQVIA, Lundbeck, Mylan, Recordati, Sage and Schwabe; and he has served on speaker bureaus for Abbott, Angelini, Aspen Farmaceutica S.A., Biogen, Janssen, Lundbeck, Recordati, Sage, Sanofi, Schwabe, Servier, Sun Pharma and Vifor. Without any relevance to this work, R. Lanzenberger received investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MR and travel grants and/or conference speaker honoraria from Bruker BioSpin, Shire, AstraZeneca, Lundbeck A/S, Dr. Willmar Schwabe GmbH, Orphan Pharmaceuticals AG, Janssen-Cilag Pharma GmbH, Heel and Roche Austria GmbH. in the years before 2020. He has been a shareholder of the start-up company BM Health GmbH, Austria since 2019. M. Hacker received consulting fees and/or honoraria from Bayer Healthcare BMS, Eli Lilly, EZAG, GE Healthcare, Ipsen, ITM, Janssen, Roche, Siemens Healthineers. G.S. Kranz declares that he received a conference speaker honorarium from Roche, AOP Orphan and Pfizer. The other authors do not report any conflict of interest.
